Apellis Pharmaceuticals Competitors

Apellis Pharmaceuticals (NASDAQ:APLS) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Apellis Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Apellis Pharmaceuticals and Grifols, as provided by MarketBeat.com.

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, suggesting a potential upside of 180.16%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Grifols.

Valuation and Earnings

This table compares Apellis Pharmaceuticals and Grifols' top-line revenue, earnings per share (EPS) and valuation.

Grifols has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Apellis Pharmaceuticals and Grifols' net margins, return on equity and return on assets.

Apellis Pharmaceuticals (NASDAQ:APLS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Apellis Pharmaceuticals and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Insider & Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Apellis Pharmaceuticals and Teva Pharmaceutical Industries, as provided by MarketBeat.

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, suggesting a potential upside of 180.16%. Teva Pharmaceutical Industries has a consensus price target of $11.80, suggesting a potential upside of 8.46%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Apellis Pharmaceuticals is more favorable than Teva Pharmaceutical Industries.

Valuation & Earnings

This table compares Apellis Pharmaceuticals and Teva Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

Apellis Pharmaceuticals has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Apellis Pharmaceuticals has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Summary

Apellis Pharmaceuticals beats Teva Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Apellis Pharmaceuticals and Bausch Health Companies' net margins, return on equity and return on assets.

Insider & Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Apellis Pharmaceuticals and Bausch Health Companies, as provided by MarketBeat.

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, suggesting a potential upside of 180.16%. Bausch Health Companies has a consensus price target of $32.5833, suggesting a potential upside of 7.68%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Apellis Pharmaceuticals is more favorable than Bausch Health Companies.

Valuation & Earnings

This table compares Apellis Pharmaceuticals and Bausch Health Companies' top-line revenue, earnings per share (EPS) and valuation.

Apellis Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Apellis Pharmaceuticals has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Summary

Apellis Pharmaceuticals beats Bausch Health Companies on 7 of the 13 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Volatility and Risk

Dr. Reddy's Laboratories has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Dr. Reddy's Laboratories and Apellis Pharmaceuticals, as reported by MarketBeat.com.

Dr. Reddy's Laboratories currently has a consensus target price of $70.00, suggesting a potential upside of 10.97%. Apellis Pharmaceuticals has a consensus target price of $124.6154, suggesting a potential upside of 180.16%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Earnings & Valuation

This table compares Dr. Reddy's Laboratories and Apellis Pharmaceuticals' gross revenue, earnings per share and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Dr. Reddy's Laboratories and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Dr. Reddy's Laboratories beats Apellis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Profitability

This table compares Maravai LifeSciences and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Maravai LifeSciences and Apellis Pharmaceuticals' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent ratings for Maravai LifeSciences and Apellis Pharmaceuticals, as reported by MarketBeat.com.

Maravai LifeSciences currently has a consensus target price of $38.1250, suggesting a potential upside of 3.18%. Apellis Pharmaceuticals has a consensus target price of $124.6154, suggesting a potential upside of 180.16%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Maravai LifeSciences.

Insider & Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Apellis Pharmaceuticals beats Maravai LifeSciences on 4 of the 7 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Apellis Pharmaceuticals and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Apellis Pharmaceuticals and Jazz Pharmaceuticals' revenue, earnings per share and valuation.

Jazz Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Apellis Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Institutional & Insider Ownership

81.2% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 9.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Apellis Pharmaceuticals and Jazz Pharmaceuticals, as provided by MarketBeat.

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, suggesting a potential upside of 180.16%. Jazz Pharmaceuticals has a consensus price target of $186.7778, suggesting a potential upside of 12.27%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Apellis Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Apellis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.